Infectious Complications in Organ Transplant Recipients

  • Shimon Kusne
  • Ron Shapiro
Chapter
Part of the Immunology and Medicine Series book series (IMME, volume 29)

Abstract

In this section, the general principles of infectious complications in transplant recipients will be reviewed, and the diseases associated with specific pathogens and their management will be discussed. While prophylaxis against the more common organisms has generally been employed, in recent years the concept of preemptive therapy has been introduced, with the goal of providing more selective prevention of disease. There has been significant progress made in the development of new and sensitive diagnostic methods, e.g. the introduction of PCR techniques. These new modalities offer the promise of allowing clinicians to diagnose infectious complications early and to intervene before infection becomes symptomatic.

Keywords

Liver Transplant Transplant Recipient Invasive Aspergillosis Liver Transplant Recipient Cryptococcal Meningitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Linden PK; Pasculle AW; Manez R; Kramer DJ; Fung JJ; Pinna AD; et al. Clin Infect Dis 1996 Apr; 22(4): 663–70PubMedCrossRefGoogle Scholar
  2. 2.
    Risk Factors Associated with Vancomycin Resistant Enterococcus faecium (VREF) Bacteremia in Liver Transplant Recipients (abstract). Kusne S., Molmenti E., Krystofiak S., Rakela J., Fung J. The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 1997.Google Scholar
  3. 3.
    Recommendations for preventing the spread of vancomycin resistance. Centers for Disease Control and Prevention. MMWR 1994; 59:25758–25763Google Scholar
  4. 4.
    Infection-control measures reduce transmission of vancomycin-resistant enterococci in an ending endemic setting. Montecalvo MA; Jarvis WR; Uman J; Shay DK; Petrullo C; Rodney K; et al. Ann Intern Med 1999 Aug 17;131(4):269–72PubMedGoogle Scholar
  5. 5.
    Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant grampositive bacterial infections. Chien JW; Kucia ML; Salata RA. Clin Infet Dis 2000 Jan;30(1):146–51CrossRefGoogle Scholar
  6. 6.
    Listeria faecal carriage by renal transplant recipients, haemodialysis patients and patients in general practice: its relation to season, drug therapy, foreign travel, animal exposure and diet. MacGowan AP; Marshall RJ; MacKay IM; Reeves DS. Epidemiol Infect 1991 Feb; 106(1): 157–66PubMedCrossRefGoogle Scholar
  7. 7.
    Two cases of progressive multifocal leukoencephalopathy after renal transplantation. Reznik M; Halleux J; Urbain E; Mouchette R; Castermans P; Beaujean M. Acta Neuropathol Suppl (Berl) 1981; 7:189–91CrossRefGoogle Scholar
  8. 8.
    Listeriosis in renal transplant recipients: report of an outbreak and review of 102 cases. Stamm AM; Dismukes WE; Simmons BP; Cobbs CG; Elliot A; Budrich P; et al. Rev Infect Dis 1982 May-Jun;4(3):665–82PubMedCrossRefGoogle Scholar
  9. 9.
    Report of 24 cases of Listeria monocytogenes infection at the University of Miami Medical Center. Qayyum QJ; Scerpella EG; Moreno JN; Fischl MA. Rev Invest Clin 1997 Jul-Aug;49(4):265–70PubMedGoogle Scholar
  10. 10.
    Listeria monocytogenes hepatitis in a liver transplant recipient: a case report and review of the literature. Bourgeois N; Jacobs F; Tavares ML; Rickaert F; Deprez C; Liesnard C; et al. J Hepatol 1993 Jul;18(3):284–9PubMedCrossRefGoogle Scholar
  11. 11.
    Listerial myocarditis in cardiac transplantation. Stamm AM; Smith SH; Kirklin JK; McGiffin DC. Rev Infect Dis 1990 Sep-Oct;12(5):820–3PubMedCrossRefGoogle Scholar
  12. 12.
    Listeriosis and recurrent abortion in renal transplant recipient. Dick JP; Palframann A; Hamilton DV. J Infect 1988 May; 16(3):273–7PubMedCrossRefGoogle Scholar
  13. 13.
    Listeria monocytogenes endophthalmitis in a renal-transplant patient receiving cyclosporin. Algan M; Jonon B; George JL; Lion C; Kessler M; Burdin JC. Ophthalmologica 1990:201(1):23–7PubMedCrossRefGoogle Scholar
  14. 14.
    Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Spitzer PG; Hammer SM; Karchmer AW. Rev Infect Dis 1986 May-Jun;8(3):427–30PubMedCrossRefGoogle Scholar
  15. 15.
    Legionellosis in heart transplant recipients. Horbach I; Fehrenbach FJ. Infection 1990 Nov-Dec;18(6):361–3PubMedCrossRefGoogle Scholar
  16. 16.
    Epidemiology of legionella pneumonia and factors associated with legionellarelated mortality at a tertiary care center. Tkatch LS; Kusne S; Irish WD; Krystofiak S; Wing E. Clin Infect Dis 1998 Dec;27(6): 1479–86PubMedCrossRefGoogle Scholar
  17. 17.
    More then 10 years of unrecognized nosocomial transmission of legionnaires’ disease among transplant patients. Kool JL; Fiore AE; Kioski CM; Brown EW; Benson RF; Pruckler JM; et al. Infect Control Hosp Epidemiol 1998 Dec; 19(12): 898–904PubMedCrossRefGoogle Scholar
  18. 18.
    Epidemiology, bacteriology and control of an outbreak of Nocardia asteroides infection on a liver unit. Sahathevan M; Harvey FA; Forbes G; 0; Grady J; Gimson A; Bragman S; et al. J Hosp Infect 1991 Jun;18 Suppl A:473–80Google Scholar
  19. 19.
    Disseminated subcutaneous Nocardia asteroides abscesses in a patient after bone marrow transplantation. Hodohara K; Fujiyama Y; Hiramitu Y; Sumiyoshi K; Kitoh K; Hosoda S; et al. Bone Marrow Transplant 1993 Apr; 11(4):341–3PubMedGoogle Scholar
  20. 20.
    Nocardiosis in liver ttransplantation: variation in presentation, diagnosis and therapy. Forbes GM; Harvey FA; Philpott-Howard JN; O’Grady JG; Jensen RD; Sahathevan M; et al. J Infect 1990 Jan;20(1):11–9PubMedCrossRefGoogle Scholar
  21. 21.
    Nocardia infection in patients with liver transplants or chronic liver disease: radiologic findings. Raby N; Forbes G; Williams R. Radiology 1990 Mar;174(3Ptl): 713-6Google Scholar
  22. 22.
    Trimethoprin/sulfamethoxazole-resistant Nocardia asteroides causing multiple hepatic abscesses. Successful treatment with ampicillin, amikacin, and limited computed tomography-guided needle aspiration. Cockerill FR 3d; Edson RS; Roberts GD; Waldorf JC. Am J Med 1984 Sep;77(3):558–60PubMedCrossRefGoogle Scholar
  23. 23.
    Foreign born is the most important risk factor for Tuberculosis infection in adult liver transplant recipients (abstract). Wada S., Kusne S., Fung J., Rakela J. The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996.Google Scholar
  24. 24.
    Nosocomial outbreak of tunerculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of Mycobaterium tuberculosis isolates. Jereb JA; Burwen DR; Dooley SW; Haas WH; Crawford JT; Geiter LJ; et al. J Infect Dis 1993 Nov; 168(5): 1219–24PubMedCrossRefGoogle Scholar
  25. 25.
    Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Work-ing Group on Anti-Tuberculosis Drug Resistance Surveillance. Pablos-Mendez A; Raviglione MC; Laszlo A; Binkin N; Rieder HL; Bustreo F; et al. N Engl J Med 1998 Jun4;338(23):1641–9PubMedCrossRefGoogle Scholar
  26. 26.
    Spread of strain W, a highly drug-resistant strain of Mycobaterium tuberculosis, across the United States. Agerton TB; Valway SE; Blinkhorn RJ; Shilkret KL; Reves R; Schlüter WW; et al. Clin Infect Dis 1999 Jul;29(1):85–92;discussion 93-5PubMedCrossRefGoogle Scholar
  27. 27.
    Anergy panel and purified protein derivative(PPD) skin testing are poor tuberculosis(TB) screening method in adult liver transplant candidates (abstract). Kusne S., Irish W., Geary K., Ondick L.f Rakela J.f Fung J. The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September, 1995.Google Scholar
  28. 28.
    Workshop on CMV disease; definitions, clinical severity scores, and new syndromes. Ljungman P., Plotkin SA. Scand J Infect Dis Suppl 1995: 99: 87–89.Google Scholar
  29. 29.
    Definitions of cytomegalovirus infection and disease, page 233-237. Ljungman P., Griffiths P. In Multidisciplinary approach to understanding cytomegalovirus desease. S Michelson and AS Plotkin eds. Elsevier Science Publishers, 1993.Google Scholar
  30. 30.
    Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients. Revello MG, Percivalle E, Matteo AD, Morini F, Gerna G. Journal of General Virology 1992: 73: 437–442.PubMedCrossRefGoogle Scholar
  31. 31.
    Direct detection of cytomegalovirus in peripheral blood leukocytes—a review of the antigenemia assay and polymerase chain reaction. The TH, Van Der Ploeg M, Van Den Berg AP, Vlieger AM, Van Der Giessen M, Van Son WJ. Transplantation 1992: 54: 193–198.PubMedCrossRefGoogle Scholar
  32. 32.
    Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Littler E, Stuart AD, Chee MS. Nature 1992: 358: 160–164.PubMedCrossRefGoogle Scholar
  33. 33.
    A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Sullivan V, Biron KK, Talarico C, Stanat SC, Davis M, Pozzi LM, et al. Antimicrobial Agents and chemotherapy 1993: 37: 19–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Annals of Internal Medicine 1988: Nov 15: 783–788.Google Scholar
  35. 35.
    Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group. Ljungman P, et al. Clinical Infectious Diseases 1992: 14: 831–835.PubMedCrossRefGoogle Scholar
  36. 36.
    Preemptive therapy in immunocompromised hosts. Rubin RH. The New England Journal of Medicine 1991: 324: 1057–1059.PubMedCrossRefGoogle Scholar
  37. 37.
    Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegaloviurs disease in liver-transplant recipients. Gane E, Saliba F, Valdecasas GJC, O’grady J, Pescovitz MD, Lyman S, et al. The Lancet 1997: 350: 1729–1733.CrossRefGoogle Scholar
  38. 38.
    CMV PP65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of CMV disease in adult liver transplant recipients. Kusne S, Grossi P, Irish W, St.George K, Rinaldo C, Rakela J, et al. Transplantation, 1999, October;68(8): 1125–1131.PubMedCrossRefGoogle Scholar
  39. 39.
    Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients; evidence of a marrow-suppressive role for HHV-6 in vivo. Drobyski WR; Dunne WM; Burd EM; Knox KK; Ash RC; Horowitz MM; et al. J Infect Dis 1993 Mar; 167(3):735–9PubMedCrossRefGoogle Scholar
  40. 40.
    Human herpesvirus-6 meningoencephalitis in a recipient of an unrelated allo-geneic bone marrow transplantation. Rieux C; Gautheret-Dejean A; Challine Lehmann D; Kirch C; Agut H; Vernant JP. Transplantation 1998 May 27;65(10): 1408–11PubMedCrossRefGoogle Scholar
  41. 41.
    Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Singh H; Carrigan DR; Gayowski T; Singh J; Marino IR. Transplantation 1995 Dec 15;60(ll):1355–7PubMedGoogle Scholar
  42. 42.
    Human herpesvirus-6 in trasplantaron: an emerging pathogan. Singh H; Carrigan DR. Ann Intern Med 1996 Jun 15; 124(12): 1065–71PubMedGoogle Scholar
  43. 43.
    Seroconversion to human herpevirus 6 following liver transplantation is a marker of cytomegalovirus disease. Dockrell DH; Prada J; Jones MF; Patel R; Badley AD; Harmsen WS, et al. J Infect Dis 1997 Nov; 176(5):1135–40PubMedCrossRefGoogle Scholar
  44. 44.
    Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Ratnamohan VM; Chapman J; Howse H; Bovington K; Roberston P; Byth K; et al. Transplantation 1998 Oct 15;66(7):877–82PubMedCrossRefGoogle Scholar
  45. 45.
    Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG, et al. J Infect Dis 1998; 178(6): 1783–6PubMedCrossRefGoogle Scholar
  46. 46.
    Clinical relevance of human Herpesvirus-6 in liver transplant recipients: role of pathogenesis of fungal infections, neurologic complications, and impact on outcome. Rogers J; Singh N; Carrigan DR; Rohal S; Kusne S; Knox KK. Transplantation 2000, in press.Google Scholar
  47. 47.
    Susceptiblity of human herpesvirus 6 to antivirals in vitro. Burns WH; Sandford GR. J Infect Dis 1990 Sep;162(3):634–7PubMedCrossRefGoogle Scholar
  48. 48.
    Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatmeent with ganciclovir. Mookerjee BP; Vogelsang G. Bone Marrow Transplant 1997 Nov;20(10):905–6PubMedCrossRefGoogle Scholar
  49. 49.
    Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients; does it have clinical significance? Wang FZ; Linde A; Hagglund H; Testa M; Locasciulli A; Ljungman P. Clin Infect Dis 1999 Mar;28(3):562–8PubMedCrossRefGoogle Scholar
  50. 50.
    Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Rothwell WS; Gloor JM; Morgenstern BZ; Milliner DS. Transplantation 1999 Jul 15;68(1): 158–61PubMedCrossRefGoogle Scholar
  51. 51.
    Acyclovir and renal transplantation. Pettersson E; Eklund B; Hockerstedt K; Salmela K; Ahonen J. Scand J Infect Dis Suppl 1985; 47:145–8PubMedGoogle Scholar
  52. 52.
    Famciclovir: review of clinical efficacy and safety. Cirelli R; Herne K; McCrary M; Lee P; Tyring SK. Antiviral Res 1996 Mar;29(2-3): 141–51PubMedCrossRefGoogle Scholar
  53. 53.
    Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Snoeck R; Andrei G; De Clercq E. Drugs 1999 Feb; 57(2): 187–206PubMedCrossRefGoogle Scholar
  54. 54.
    Varicella vaccination in children after bone marrow transplantion. Sauebrei A: Prager J; Hengst U; Zintl F; Wutzler P. Bone Marrow Tranplant 1997 Sep;20(5): 381–3CrossRefGoogle Scholar
  55. 55.
    Attenuated varicella virus vaccine in children with renal tranplants. Zamora I; Simon JM; Da Silva ME; Piqueras AI. Pediatr Nephrol 1994 Apr;8(2): 190–2PubMedCrossRefGoogle Scholar
  56. 56.
    Varicella in pediatric renal transplant recipients. Lynfield R; Herrin JT; Rubin RH. Pediatrics 1992 Aug;90(2 Pt l):216–20PubMedGoogle Scholar
  57. 57.
    Persistence of protective immunity after postexposure prophylaxis of varicella with oral aciclovir in the family setting. Yoshikawa T; Suga S; Kozawa T; Kawaguchi S; Asano Y. Arch Dis Child 1998 Jan;78(1):61–3PubMedCrossRefGoogle Scholar
  58. 58.
    Varicella-zoster virus-specific cellular immunity in subjects given acyclovir after household chicken pox exposure. Kumagai T; Kamada M; Igarashi C; Yuri K; Furukawa H; Chiba S; et al. J Infect Dis 1999 Sep;180(3):834–7PubMedCrossRefGoogle Scholar
  59. 59.
    The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Chadbum A; Chen JM; Hsu DT; Frizzera G; Cesarman E; Garrett TJ; et al. Cancer 1998 May:15;82(10): 1978–87CrossRefGoogle Scholar
  60. 60.
    Pretransplantation assessment of the risk of lymphoproliferative disorder. Walker RC; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; et al. Clin Infect Dis 1995 May;20(5): 1346–53PubMedCrossRefGoogle Scholar
  61. 61.
    Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Starzl TE; Nalesnik MA; Porter KA; Ho M; Iwatsuki S; Griffith BP; et al. Lancent 1984 Mar 17;l(8377):583–7CrossRefGoogle Scholar
  62. 62.
    Serial measurement of Esptein-Barr viral load in periperal blood pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Green M; Cacciarelli TV; Mazariegos GV; Sigurdsson L; Qu L; Rowe DT. Tranplantation 1998 Dec 27;66(12):1641–4CrossRefGoogle Scholar
  63. 63.
    Detection of Epstein-Ban virus DNA in sera from transplant recipients with lymphoproliferative disorders. Limaye AP; Huang ML; Atienza EE; Ferrenberg JM; Corey L. J Clin Microbiol 1999 Apr;37(4): 1113–6PubMedGoogle Scholar
  64. 64.
    The Epstein-Ban virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specifity compared to the herpes smplex virus 1 thymidine kinase. Gustafson EA; Chillemi AC; Sage DR; Fingeroth JD. Antimicrob Agents Chemother 1998 Nov;42(ll):2923–31PubMedGoogle Scholar
  65. 65.
    Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Ban virus associated lymphoma. Mentzer SJ; Fingeroth J; Reilly JJ; Penine SP; Faller DV. Blood Cells Mol Dis 1998 June:24(2): 114-23Google Scholar
  66. 66.
    Lymphoproliferative disorders following allergeneic bone manow transplantation: the Vancouver experience. Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; et al. Bone Manow Transplant 1998 Nov;22(10):981–7CrossRefGoogle Scholar
  67. 67.
    Use of gene-modified virus-specific T lymphocytes to control Epstein-Ban virusrelated lymphoproliferation. Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; et al. Lancet 1995 Jan 7;345(8941):9–13PubMedCrossRefGoogle Scholar
  68. 68.
    Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Ban virus-induced lymphoma in allogeneic transplant recipients. Rooney CM; Smith CA; Ng CY; Loftin SK; Sixbey JW; Gan Y; et al. Blood 1998 Sep l;92(5):1549–55PubMedGoogle Scholar
  69. 69.
    Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative sundrome following bone marrow and organ transplantation. Fischer A; Blanche S; Le Bidois J; Bordigoni P; Gamier JL; Niaudet P; et al. N Engl J Med 1991 May 23;324(21):1451–6PubMedCrossRefGoogle Scholar
  70. 70.
    Autologous lymphokine-activated killer cell therapy of Epstein-Ban virus-positive and negative lymphoproliferative disorders arising in organ transplant recipients. Nalesnik MA; Rao AS; Furukawa H; Pham S; Zeevi A; Fung JJ, et al. Transplantation 1997 May;63(9): 1200–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy. Li PK; Tsang K; Szeto CC; Wong TY; To KF; Leung CB. Am J Kidney Dis 1998 Nov;32(5): 813–9PubMedCrossRefGoogle Scholar
  72. 72.
    Resistance to parvovirus B19 infection due to lack of virus receptor (erythocyte P antigen). Brown KE; Hibbs JR; Gallinella G; Anderson SM; Lehman ED; McCarthy P; et al. N Engl J Med 1994 Apr 28;330(17):1192–6PubMedCrossRefGoogle Scholar
  73. 73.
    Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Cohen BJ; Beard S; Knowles WA; Ellis JS; Joske D; Goldman JM; et al. Transfusion 1997 Sep;37(9):947–52PubMedCrossRefGoogle Scholar
  74. 74.
    Transfusion-transmitted disease. Lee CA. Baillieres Clin Haematol 1996 Jun; 9(2): 369–94PubMedCrossRefGoogle Scholar
  75. 75.
    B19 Parvovirus replicates in circulating cells of acutely infected patients. Kurtzman GJ; Gascon P; Caras M; Cohen B; Young NS. Blood 1988 May;71(5): 1448–54PubMedGoogle Scholar
  76. 76.
    Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Heegaard ED; Eiskjaer H; Baandrup U; Homsleth A. Scand J Infect Dis 1998;30(6):607–10Google Scholar
  77. 77.
    Parvovirus B19 infection-related complications in renal transplant recicpients: treatment with intravenous immunoglobulin. Moudgil A; Shidban H; Nast CC; Bagga A; Aswad S; Graham SL; et al. Transplantation 1997 Dec 27;64(12): 1847–50PubMedCrossRefGoogle Scholar
  78. 78.
    Post-transplantation Polyomavirus infections. Boubenider S; Hiesse C; Marchand S; Hafi A; Kriaa F; Charpentier B. J Nephrol 1999 Jan-Feb; 12(1):24–9PubMedGoogle Scholar
  79. 79.
    Human polyma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Drachenberg CB; Beskow CO; Cangro CB; Bourquin PM; Simsir A; Fink J; et al. Hum Pathol 1999 Aug:30(8):970–7PubMedCrossRefGoogle Scholar
  80. 80.
    A serological investigation of BK virus and JC virus infections in recipients of renal allografts. Andrews CA; Shah KV; Daniel RW; Hirsch MS; Rubin RH. J Infect Dis 1988 Jul; 158(1)176–81PubMedCrossRefGoogle Scholar
  81. 81.
    Human polyoma virus-associated interstitial nephritis in the allograft kidney. Randhawa PS; Finklestein S; Scantlebury V; Shapiro R; Vivas C; Jordan M; et al. Transplantation 1999 Jan 15;67(1): 103–9PubMedCrossRefGoogle Scholar
  82. 82.
    Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Binet I; Nickeleit V; Hirsch HH; Prince O; Dalquen P; Gudat F; et al. Transplantation 1999 Mar 27;67(6):918–22PubMedCrossRefGoogle Scholar
  83. 83.
    Diagnosis and management of BK Polyomavirus interstitial nephritis in renal transplant recipients. Howell DN; Smith SR; Butterly DW; Klassen PS; Krigman HR; Burchette JL Jr; et al. Transplantation 1999 Nov 15;68(9): 1279–88PubMedCrossRefGoogle Scholar
  84. 84.
    Human polyoma virus infections with JC virus and BK virus in renal transplant patients. Hogan TF; Borden EC; McBain JA; Padgett BL; Walker DL. Ann Intern Med 1980 Mar; 92(3): 373–8PubMedGoogle Scholar
  85. 85.
    Molecular evidence of simian virus 40 infections in children. Butel JS; Arrington AS; Wong C; Lednicky JA; Finegold MJ. J Infect Dis 1999 Sep;180(3):884–7PubMedCrossRefGoogle Scholar
  86. 86.
    The hepatitis C virus; overview. Purcell R. Hepatology 1997 Sep;26(3 Suppl 1): 11S–14SPubMedCrossRefGoogle Scholar
  87. 87.
    Serologic responses to hepatitis C virus is solid organ transplant recipients. Preiksaitis JK; Cockfield SM; Fenton JM; Burton NI; Chui LW. Transplantation 1997 Dec 27;64(12): 1775–80PubMedCrossRefGoogle Scholar
  88. 88.
    Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation. Berg T; Hopf U; Bechstein WO; Muller AR; Fukumoto T; Neuhaus R; et al. Transplantation 1998 July;66(2): 225–228.PubMedCrossRefGoogle Scholar
  89. 89.
    High incidence of allograft cirrhosis in hepatitis C virus genotype lb infection following transplantation: relationship with rejection episodes. Prieto M; Berenguer M; Rayon JM; Cordoba J; Arguello L; Carrasco D; et al. Hepatology 1999 Jan;29(1):250–6PubMedCrossRefGoogle Scholar
  90. 90.
    The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Vargas HE; Laskus T; Wang LF; Radkowski M; Poutous A; Lee R; et al. Liver Transpl Surg 1998 Jan;4(1):22–7PubMedCrossRefGoogle Scholar
  91. 91.
    Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Pessoa MG; Bzowej N; Berenguer M; Phung Y; Kim M; Ferrel L; et al. Hepatology 1999 Dec;30(6): 1513–20PubMedCrossRefGoogle Scholar
  92. 92.
    The non-structural 5A protein of hepatitis C virus. Pawlotsky JM; Germanidis G. J Viral Hepat 1999 Sep;6(5):343–356PubMedCrossRefGoogle Scholar
  93. 93.
    The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Wachs ME; Amend WJ; Ascher NL; Bretan PN; Emond J; Lake JR; et al. Transplantation 1995 Jan 27; 59(2): 230-4Google Scholar
  94. 94.
    Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Hendricks DA; Stowe BJ; Hoo BS; Kolberg J; Irvine BD; Neuwald PD; et al. Am J Clin Pathol 1995 Nov; 104(5):537–46PubMedGoogle Scholar
  95. 95.
    Liver Transplantation in European patients with the hepatitis B surface antigen. Samuel D; Müller R; Alexander G; Fassati L; Ducot B; Benhamou JP; et al. N Engl J Med 1993 Dec 16;329(25): 1842–7PubMedCrossRefGoogle Scholar
  96. 96.
    Infectivity of hepatic allografts with antibodies to hepatitis B virus. Dodson SF; Issa S; Araya V; Gayowski T; Pinna A; Eghtesad B; et al. Transplantation 1997 Dec l5;64(ll):1582–4PubMedCrossRefGoogle Scholar
  97. 97.
    Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Dodson SF; Bonham CA; Geller DA; Cacciarelli TV; Rakela J; Fung JJ; et al. Transplantation 1999 Oct 15;68(7): 1058-61Google Scholar
  98. 98.
    Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Terrault NA; Zhou S; McCory RW; Pruett TL; Lake JR; Roberts JP; et al. Hepatology 1998 Aug; 28(2):555–61PubMedCrossRefGoogle Scholar
  99. 99.
    Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Perrillo R; Rakela J; Dienstag J; Levy G; Martin P; Wright T; et al. Hepatology 1999 May;29(5): 1581–6PubMedCrossRefGoogle Scholar
  100. 100.
    Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipent. Mutimer D; Pillay D; Shields P; Cane P; Ratcliffe D; Martin B; et al. Gut 2000 Jan 46(1): 107–13PubMedCrossRefGoogle Scholar
  101. 101.
    Famciclover treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Wedemeyer H; Boker KH; Pethig K; Petzold DR; Flemming P; Tillmann HL; et al. Transplantation 1999 Nov 27;68(10): 1503–11PubMedCrossRefGoogle Scholar
  102. 102.
    Long term ganciclovir therapy for hepatitis B virus infection after liver transplantation. Roche B; Samuel D; Gigou M; Feray C; Virot V; Majno P; et al. J Hepatol 1999 0ct;31(4):584–92PubMedCrossRefGoogle Scholar
  103. 103.
    Risk factors for invasive fungal infections complicating orthotopic liver transplantation. Collins LA; Samore MH; Roberts MS; Luzzati R; Jenkins RL; Lewis WD. J Infect Dis 1994 Sep;170(3):644–52PubMedCrossRefGoogle Scholar
  104. 104.
    Candida Carriage in the alimentary tract of liver transplant candidates. Kusne S; Tobin D; Pasculle AW; Van Thiel DH; Ho M; Starzl TE. Transplantation 1994 Feb; 57(3): 398–402PubMedCrossRefGoogle Scholar
  105. 105.
    Candida colonization and subsequent infections in critically ill surgical patients. Pittet D; Monod M; Suter PM; Frenk E; Auckenthaler R. Ann Surg 1994 Dec;220(6):751–8PubMedCrossRefGoogle Scholar
  106. 106.
    Factors associtaed with the development of candidemia and candidemia related death among liver transplant recipients. Neito-Rodriguez JA; Kusne S; Manez R; Irish W; Linden P; Magnone M; et al. Ann Surg 1996 Jan;223(1):70–6CrossRefGoogle Scholar
  107. 107.
    “True” mycotic aneurysm of a renal artery allograft. Potti A; Danielson B; Sen K. Am J Kidney Dis 1998 Jan;31(1):E3PubMedCrossRefGoogle Scholar
  108. 108.
    Successful outcome after massive bleeding in a heart transplant recipient with mycotic aortitis. Case report. Berggren H; Berglin E; Kjellman U; Mantovani V; Nilsson B. Scand J Thorac Cardiovasc Surg 1994;28(1):45–7PubMedCrossRefGoogle Scholar
  109. 109.
    Management of mycotic rupture of the ascending aorta after heart-lung transplantation. Albes J; Haverich A; Freihorst J; von der Hardt H; Manthey-Stiers F. Ann Thorac Surg 1990 Dec;50(6):982–3PubMedCrossRefGoogle Scholar
  110. 110.
    Evaluation of lysis-centrifugation system for recovery of yeasts and filamentous fungi from blood. Bille J; Stockman L; Roberts GD; Horstmeier CD; Ilstrup DM. J Clin Microbiol 1983 Sep;18(3):469–71PubMedGoogle Scholar
  111. 111.
    Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. Walsh TJ; Hathorn JW; Sobel JD; Merz WG; Sanchez V; Maret SM; et al. N Engl J Med 1991 Apr 11;324(15):1026–31PubMedCrossRefGoogle Scholar
  112. 112.
    10 year review of invasive aspergillosis detected at necropsy. Boon AP; O’Brien D; Adams DH. J Clin Pathol 1991 Jun;44(6):452–4PubMedCrossRefGoogle Scholar
  113. 113.
    CIIS aspergillosis in organ transplantation: a clinicopathological study. Torre Cisneros J; Lopez OL; Kusne S; Martinez AJ; Starzl TE; Simmons RL; et al. J Neurosurg Psychiatry 1993 Feb;56(2):188–93CrossRefGoogle Scholar
  114. 114.
    Factors associated with invasive lung aspergillosis and the significance of positive Aspergerillus culture after liver transplantation. Kusne S; Torre-Cisneros J; Manez R; Irish W; Martin M; Fung J; et al. J Infect Dis 1992 Dec; 166(6): 1379–83PubMedCrossRefGoogle Scholar
  115. 115.
    Surgical wound infection by Aspergillus fumigatus in liver transplant recipients. Pla MP; Berenguer J; Arzuaga JA; Banares R; Polo JR; Bouza E. Diagn Micrrobiol Infect Dis 1992 Nov-Dec;15(8):703–6CrossRefGoogle Scholar
  116. 116.
    The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Horvath JA; Dummer S. Am J Med 1996 Feb; 100(2): 171–8PubMedCrossRefGoogle Scholar
  117. 117.
    Evaluation of PCR for detection of DNA specific for Aspergillus species in sera of patients with various forms of pulmonary aspergillosis. Yamakami Y; Hashimoto A; Yamagata E; Kamberi P; Karashima R; Nagai H; et al. J Clin Microbiol 1998 Dec;36(12):3619–23PubMedGoogle Scholar
  118. 118.
    Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Verweij PE; Dompeling EC; Donnelly JP; Schattenberg AV; Meis JF. Infection 1997 Mar-Apr;25(2):86–9PubMedCrossRefGoogle Scholar
  119. 119.
    Itraconazole for the treatment of pulmonary aspergillosis in heart transplant recipients. Nanas JN; Saroglou G; Anastasiou-Nana MI; Kostis EB; Petrochilou Paschou VP; Kontoyannis DA; et al. Clin Transplant 1998 Feb;12(1):30–4PubMedGoogle Scholar
  120. 120.
    Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Bernard A; Caillot D; Couallier JF; Casasnovas 0; Guy H; Favre JP. Ann Thorac Surg 1997 Nov; 64(5): 1441–7PubMedCrossRefGoogle Scholar
  121. 121.
    Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation: a case resport. Sandur S; Gordon SM; Mehta AC; Maurer JR. J Heart Lung Transplant 1999 Aug;18(8):810–3PubMedCrossRefGoogle Scholar
  122. 122.
    Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Tollemar J; Hockerstedt K; Ericzon BG; Jalanko H; Ringden O. Transplantation 1995 Jan 15;59(1):45–50PubMedCrossRefGoogle Scholar
  123. 123.
    Systemic mycoses during prophylactical use of liposomal amphotericin B (ambisome) after liver transplantation. Lorf T; Braun F; Ruchel R; Müller A; Sattler B; Ringe B. Mycoses 1999 Apr;42(l-2):47–53PubMedCrossRefGoogle Scholar
  124. 124.
    The epidemiology of cryptococcal infection in solid organ transplantation (abstract). Kusne S, Madariaga J, McCurry K, Kormos R, Fung J. The 17th Annual Scientific Meeting of The American Society of Transplant Physicians, Chicago, May 1998.Google Scholar
  125. 125.
    Cryptococcosis in a renal unit. Kong NC; Shaariah W; Morad Z; Suleiman AB; Wong YH. Aust N Z J Med 1990 Oct;20(5):645–9PubMedCrossRefGoogle Scholar
  126. 126.
    Cryptococcal meningitis after liver transplantation. Jabbour N; Reyes J; Kusne S; Martin M; Fung J. Transplantation 1996 Jan 15;61(1): 146–9PubMedCrossRefGoogle Scholar
  127. 127.
    Risk factors in necrotizing fasciitis: a case involving Cryptococcus neoformans. Marcus JR; Hussong JW; Gonzalez C; Dumanian GA. Ann Plast Surg 1998 Jan;40(1):80–3PubMedCrossRefGoogle Scholar
  128. 128.
    Disseminated cryptococcosis presenting as cellulitis with necrotizing vasculitis. Shrader SK; Watts JC; Dancik JA; Band JD. J Clin Microbiol 1986 Nov;24(5): 860–2PubMedGoogle Scholar
  129. 129.
    Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Robinson PA; Bauer M; Leal MA: Evans SG; Holtom PD; Diamond DA; et al. Clin Infect Dis 1999 Jan;28(1):82–92PubMedCrossRefGoogle Scholar
  130. 130.
    A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Saag MS; Cloud GA; Graybill JR; Sobel JD; Tuazon CU; Johnson PC; et al. Clin Infect Dis 1999 Feb;28(2):291–6PubMedCrossRefGoogle Scholar
  131. 131.
    Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Valero G; Graybill JR. Antimicrob Agents Chemother 1995 Nov;39(ll):2588–90PubMedCrossRefGoogle Scholar
  132. 132.
    Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an ail oral regimen. Singh N; Gayowski T; Marino IR. Transplint 1998; 11(1):63–5CrossRefGoogle Scholar
  133. 133.
    Malaria infection in kidney transplant recipients. Lee PC; Lee PY; Lei HY; Chen FF; Tseng JY; Ching YT. Transplant Proc 1994 Aug;26(4):2099–100PubMedGoogle Scholar
  134. 134.
    Pneumocystis carinii pneumonia: the status of Pneumocystis biochemistry. Kaneshiro ES. Int J Parasitol 1998 Jan;28(1):65–84PubMedCrossRefGoogle Scholar
  135. 135.
    Pneumocystis carinii infection in heart transplant recipients. Efficacy of a weekend prophylaxis schedule. Munoz P; Munoz RM; Palomo J; Rodriguez-Creixems M; Munoz R; Bouza E. Medicine (Baltimore) 1997 Nov;76(6):415–22CrossRefGoogle Scholar
  136. 136.
    Pneumocystis carinii pneumonia in renal transplant recipients. Branten AJ; Beckers PJ; Tiggeler RG; Hoitsma AJ. Nephrol Dial Transplant 1995; 10(7): 1194–7PubMedGoogle Scholar
  137. 137.
    Trimethoprin-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation-how effective and for how long? Kramer MR; Stoehr C; Lewiston NJ; Starnes VA; Theodore J. Transplantation 1992 Mar;53(3):586–9PubMedCrossRefGoogle Scholar
  138. 138.
    Pneumocystis carinii pneumonia in heart transplant recipients. Grossi P; Ippoliti GB; Goggi C; Cremaschi P; Scaglia M; Minoli L. Infection 1993 Mar-Apr;21(2): 75–9PubMedCrossRefGoogle Scholar
  139. 139.
    Transmission of Pneumocystis carinii from AIDS patients to other immunsuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant recipients. Chave JP; David S; Wauters JP; Van Melle G; Francioli P. AIDS 1991 Aug:5(8):927–32PubMedCrossRefGoogle Scholar
  140. 140.
    Comparison of DNA amplification and immunofluorescence for detecting Pneumocystis carinii in patients receiving immunosuppressive therapy. Leigh TR; Wakefield AE; Peters SE; Hopkin JM; Collins JV. Transplantation 1992 Sep;54(3): 468–70PubMedCrossRefGoogle Scholar
  141. 141.
    Diagnosis of Pneumocystis carinii pneumonia: immunofluorescence staining, simple PCR or nPCR. Khan MA; Farrag N; Butcher P. J Infect 1999 Jul;39(1): 77–80PubMedCrossRefGoogle Scholar
  142. 142.
    Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis carinii infection in a liver transplant patient receiving tacrolimus. Kleindienst R; Fend F; Prior C; Margreiter R; Vogel W. Clin Transplant 1999 Feb;13(lPtl):65–7PubMedCrossRefGoogle Scholar
  143. 143.
    Pneumocystis carinii pneumonia. Schliep TC; Yarrish RL. Semin Respir Infect 1999 Dec; 14(4):333–43PubMedGoogle Scholar
  144. 144.
    Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Hughes WT. Clin Infect Dis 1998 Jul;27(1): 191–204PubMedCrossRefGoogle Scholar
  145. 145.
    Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Gordon SM; LaRosa SP; Kalmadi S; Arroliga AC; Avery RK; Truesdell-LaRosa L; et al. Clin Infect Dis 1999 Feb;28(2):240–6PubMedCrossRefGoogle Scholar
  146. 146.
    Utility of inhaled penatmidine prophylaxis in lung transplant recipients. Nathan SD; Ross DJ; Zakowski P; Kass RM; Koerner SK. Chest 1994 Feb;105(2):417–20PubMedCrossRefGoogle Scholar
  147. 147.
    Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Saukkonen K; Garland R; Koziel H. Chest 1996 May; 109(5): 1250–5PubMedCrossRefGoogle Scholar
  148. 148.
    Dapsone-induced methemoglobinemia. Ward KE; McCarthy MW. Ann Pharmacother 1998 May; 32(5): 549–53PubMedCrossRefGoogle Scholar
  149. 149.
    Atovaquone suspension compared with aeosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. Chan C; Montaner J; Lefebvre EA; Morey G; Dohn M; Mclvor RA; et al. J Infect Dis 1999 Aug; 180(2):369–76PubMedCrossRefGoogle Scholar
  150. 150.
    Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH JR; et al. N Engl J Med 1998 Dec 24;339(36):1889–95PubMedCrossRefGoogle Scholar
  151. 151.
    Primary and reactivated toxoplasma infection in patients with cardiac transplants. Clinical spectrum and problems in diagnosis in a defined population. Luft BJ; Naot Y; Araujo FG; Stinson EB; Remington JS. Ann Intern Med 1983 Jul;99(1):27–31PubMedGoogle Scholar
  152. 152.
    Toxoplasmosis in heart transplant recipients. Gallino A; Maggiorini M; Kiowski W; Martin X; Wunderli W; Schneider J; et al. Eur J Clin Microbiol Infect Dis 1996 May;15(5):389–93PubMedCrossRefGoogle Scholar
  153. 153.
    Cytomegalovirus infections and toxoplasmosis in heart transplant recipients in Sweden. Andersson R; Sandberg T; Berglin E; Jeansson S. Scand J Infect Dis 1992; 24(4):411–7PubMedCrossRefGoogle Scholar
  154. 154.
    Transmission of Toxoplasma gondii infection by liver transplantation. Mayes JT; O’Conner BJ; Avery R; Castellani W; Carey W. Clin Infect Dis 1995 Sep;21(3): 511–5PubMedCrossRefGoogle Scholar
  155. 155.
    Transmission of Toxoplasmosis by renal transplant. Mejia G; Leiderman E; Builes M; Henao J; Arbelaez M; Arango JL; et al. Am J Kidney Dis 1983 May; 2(6):615–7PubMedGoogle Scholar
  156. 156.
    Toxoplasmosis of donor and recipient hearts after heterotopic cardiac transplantation. Rose AG; Uys CJ; Novitsky D; Cooper DK; Barnard CN. Arch Pathol Lab Med 1983 Jul; 107(7): 368–73PubMedGoogle Scholar
  157. 157.
    Diagnosis of toxoplasma infection in cardiac transplant recipients using polymerase chain reaction. Holliman R; Johnson J; Sawa D; Cary N; Wreghitt T. J Clin Pathol 1992 Oct;45(10):931–2PubMedCrossRefGoogle Scholar
  158. 158.
    Toxoplasmosis in cardiac transplantation. Hakim M, Esmore D, Wallwork J, English TA, Wreghitt T. Br Med J 1986 Apr;292(6528): 1108CrossRefGoogle Scholar
  159. 159.
    Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. Orr KE; Gould FK; Short G; Dark JH; Hilton CJ; Corris PA; et al. J Infect 1994 Nov;29(3):249–53PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • Shimon Kusne
    • 1
  • Ron Shapiro
    • 2
  1. 1.Departments of Medicine and SurgeryUniversity of PittsburghPittsburghUSA
  2. 2.Department of SurgeryUniversity of PittsburghPittsburghUSA

Personalised recommendations